Our work shows that a treatment approach consisting of suppressed p190RhoGAP expression into tumours, which keeps RhoA active, combined with inactivation of p110δ PI3K in macrophages almost totally blocks melanoma and SCC progression. Here, ARHGAP35 is linked to neoplasm.